About

About

Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

About Us

Immunic Therapeuctics

Immunic is developing orally administered, small molecule programs: The company’s lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis and which has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis, selectively inhibits activated immune cells and shows combined anti-inflammatory, anti-viral and neuroprotective effects. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it is currently in preparations for a phase 2 clinical trial.

Immunic, Inc. is headquartered in New York City. Its subsidiary, Immunic AG, is based in Gräfelfing near Munich, Germany, where the company’s research and development activities are conducted.

Immunic AG was founded in 2016 with headquarters in Planegg-Martinsried, Germany. Since April 2019, the company has been operating under the name Immunic, Inc. with its registered office in the United States and has been trading on the Nasdaq Stock Market under the ticker symbol ”IMUX.”

Management

Chief Executive Officer,
President and Director
Chief Scientific Officer
Chief Medical Officer
Chief Business Officer
Chief Financial Officer
General Counsel
Executive Chairman

Board of Directors

Executive Chairman
Lead Independent Director
Chief Executive Officer,
President and Director
Independent Director
Independent Director
Independent Director
Independent Director
Independent Director

Scientific-Medical Advisory Board

Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
Stanford University School of Medicine

Questions?
Get in touch.

Immunic Inc, ( Nasdaq: IMUX ) Stock Quote:

Loading data...

Currency in USD. Quote data delayed at least 15 minutes.